- Company
- Aldactone, which was frequently sold out, is resupplied
- by Apr 2, 2021 06:05am
- Pfizer Korea's diuretic drug Aldactone, which was often sold out, is scheduled to resume supply. According to the distribution industry on the 27th, the supply of Aldactone (Spironolactone) 25mg is expected to resume from the 29th. It was earlier than the April 8th, the resupply date originally expected by the company. Aldactone is oft
- Company
- Only hope for pancreatic cancer Onivyde seeking for coverage
- by Eo, Yun-Ho Apr 1, 2021 06:08am
- The pancreatic cancer with highly unmet medical needs may welcome a newly listed drug. The pharmaceutical industry sources reported Servier Korea’s Onivyde (Irinotecan Hydrochloride) would be deliberated by the Health Insurance Review and Assessment Service (HIRA) Drug Reimbursement Evaluation Committee (DREC). Requested for the Nationa
- Policy
- Addpharma, entering phase 3 of low-dose Dutasteride
- by Lee, Tak-Sun Apr 1, 2021 06:06am
- Addpharma, a subsidiary of Yuhan's improved drug development, has entered phase 3 clinical trials of low-dose tablets of Dutasteride (Avodart, GSK), a hair loss treatment. Currently, Dutasteride is already on the market, but the value of Addpharma's developed products is high as there is no low dose product. The MFDS approved Addpharm
- Policy
- Baricitinib, Heparin, & NOAC were added as COVID-19 benefits
- by Lee, Jeong-Hwan Apr 1, 2021 06:05am
- Benefits are recognized when Baricitinib is co-administered with Remdesivir for the treatment of COVID-19. Low-molecular-weight heparin and new anticoagulant (NOAC) are also newly added as COVID-19 benefits. Lopinavir / Ritonavir (combination therapy), Hydroxychloroquine, and Ribavirin are eliminated from drugs covered by COVID-19. On the
- Policy
- NECA-KSID publish COVID-19 clinical treatment guideline
- by Lee, Hye-Kyung Apr 1, 2021 06:05am
- The South Korean clinical experts issued advices each on anti-COVID-19 antiviral drug (remdesivir, hydroxychloroquine, lopinavir, ritonavir and favipiravir), steroid, interleukin inhibitor, interferon, convalescent plasma therapy and general intravenous immunoglobulin. For antibody treatments with social issues, such as Rekirona, the experts
- Policy
- Tamsulosin-mirabegron drug opens competition in Korea
- by Lee, Tak-Sun Apr 1, 2021 06:05am
- KyungDong Pharmaceutical is to start a Phase III trial on a combination drug consisting of a prostatomegaly treating agent tamsulosin and an overactive bladder treating agent mirabegron. The drug is expected to begin a commercialization race against Dongkoo Bio & Pharma that already received approval on Phase III trial. Without any prec
- Policy
- Generic for Arcoxia were first approved
- by Lee, Tak-Sun Apr 1, 2021 06:05am
- Generic for Arcoxia (Etoricoxib, MSD Korea), an anti-inflammatory analgesic drug, was first approved on the 25th. The first licensed companies also succeeded in avoiding patents and obtained generic exclusivity. The MFDS approved four generic of Etoricoxib on the 25th. Boryung Etoricoxib 30mg, Arlico's Alicoxib 30mg, Reyon's Ecoxia, and D
- Opinion
- [Reporter’s Eye] How was working from home for a year?
- by Kim, Jin-Gu Mar 31, 2021 06:09am
- A year has passed since the COVID-19 has bled into people’s daily lives. The pharmaceutical industry also has faced big changes and working from home was one the biggest changes. Although it was forcefully introduced, the work from home system, unlike the beginning of the outbreak, became a norm&8212;the office staffs have been working
- Company
- Equfina can be prescribed at general hospitals
- by Eo, Yun-Ho Mar 31, 2021 06:08am
- Equfina, a treatment for Parkinson's disease from Esai, can be prescribed in general hospitals. According to related industries, Equfina (Safinamide) has passed the drug committee (DC) of Seoul National University Hospital and Asan Medical Center among Big 5 medical institutions, and is undergoing landing procedures at major medical institu
- Company
- “EMA authorizes Rekirona, sales projected at KRW 1.2 tln”
- by Kim, Jin-Gu Mar 31, 2021 06:06am
- The financial experts project Celltrion's COVID-19 monoclonal antibody treatment Rekirona injection’s (regdanvimab) sales in Europe would hit 1.2 trillion won as the European Medicines Agency (EMA) has granted conditional approval on the treatment. Leveraged by the Rekirona sales in Europe, the experts also projected Celltrion’s annual
